Fundraising Fox
/Companies
Sign in

Sensulin

2 known investors

Find your way into Sensulin

Sign up to see every warm intro you have to Sensulin

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Sensulin team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.

BiotechMedical Devices

Founders & leadership

DBDan Bradbury
Dan BradburyExecutive Chairman and Co-FounderDan Bradbury is Executive Chairman and Co-Founder of Sensulin, a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for diabetes. He has over 40 years of experience in life sciences executive roles focused on business strategy and bringing novel medicines to market.
MMMike Moradi
Mike MoradiCEOMike Moradi is co-founder and CEO of Sensulin, a biopharmaceutical company developing glucose-responsive insulin therapies for diabetes. He brings 25 years of experience founding and leading ventures in biotech and nanotechnology, including prior roles at eyeCRO and Unidym (acquired by Wisepower), and holds a Wharton Executive Education certificate in Corporate Governance.

Board

AA
Ananth AnnapragadaFounder
CRChristopher Rhodes
Christopher RhodesFounder

Investors · 2

Cortado Ventureslisted by Cortado VenturesOklahoma City

How we know: Cortado Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
BiPar SciencesBiopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
DiabetesA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as Sensulin.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase ISTTR2014$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Sensulin do?
Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.
Who founded Sensulin?
Sensulin was founded by Dan Bradbury.
Who are Sensulin's investors?
Sensulin's investors include BioBrit, Cortado Ventures.